Prospective evaluation of the achievement of mucosal healing with anti-TNF-α therapy in a paediatric Crohn's disease cohort

Journal of Crohn's and Colitis

Volumn 10, Issue 1, 2016, Pages 5-12

  Nuti, Federica ^a   Civitelli, Fortunata ^a   Bloise, Silvia ^a   Oliva, Salvatore ^a   Aloi, Marina ^a   Latorre, Giuseppe ^a   Viola, Franca ^a   Cucchiara, Salvatore ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Agents; Anti TNF ; Mucosal healing; paediatric Crohn's disease

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; INFLIXIMAB; METHOTREXATE; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ARTICLE; BIOLOGICAL THERAPY; CHILD; CLINICAL ARTICLE; CROHN DISEASE; DEMOGRAPHY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HEALING; HUMAN; IMMUNOTHERAPY; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MUCOSAL HEALING; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIMPLE ENDOSCOPIC SCORE FOR CROHN DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; EVALUATION STUDY; INTESTINE MUCOSA; KAPLAN MEIER METHOD; NONPARAMETRIC TEST; ODDS RATIO; PATHOPHYSIOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ADALIMUMAB; ADOLESCENT; BIOLOGICAL PRODUCTS; CHILD; COHORT STUDIES; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; MALE; ODDS RATIO; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84963784381     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv126     Document Type: Article

References (34)

1. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39
2. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008;135:1106-13
3. Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn's disease: comparison between childhood-and adult-onset disease. Inflamm Bowel Dis 2010;16:953-61
4. Sauer CG, Kugathasan S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Med Clin North Am 2010;94:35-52
5. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. IBD 2002;8:244-250
6. Romberg-Camps MJ, Dagnelie PC, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009;104:371-83
7. Baert F, Moortgat L, Van Assche G, et al., Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8
8. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29
9. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009;15:375-82
10. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95
11. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301
12. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42
13. Rutgeerts P, Van Assche G, Sandborn WJ, et al., EXTEND Investigators. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-1111
14. Rismo R, Olsen T, Ciu G, et al. The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease. Scand J Gastroenterol 2012; 47: 1200-10
15. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013;15:315
16. Molander P, Sipponen T, Kemppainen H, et al. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis 2013 1;7:730-5
17. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004;36:342-7
18. Kierkus J, Dadalski M, Szymanska E, et al. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease. Eur J Gastroenterol Hepatol 2012;24:495-500
19. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SESCD. Gastrointest Endosc 2004;60:505-512
20. Hyams J, Crandall W, Kugathasan S, et al. REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderateto-severe Crohn's disease in children. Gastroenterology 2007;132:863-73
21. De Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of infliximab maintenance treatment in pediatric Crohn's disease is limited. Aliment Pharmacol Ther 2011; 33:243-250
22. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009; 15:816-822
23. Crombè V, Salleron J, Savaye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2011;17:2144-52
24. Assa A, Hartman C, Weiss B, et al. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohns Colitis 2013;7:369-76
25. Nuti F, Viola F, Civitelli F, et al. Biological therapy in a pediatric Crohn disease population at a referral center. J Pediatr Gastroenterol Nutr 2014;58:582-7
26. Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1683-7
27. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderateto-severe pediatric Crohn's disease. Am J Gastroenterol 2009;104:2566-71
28. Rosh JR, Lerer T, Markowitz J, et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-9
29. Colombel JF, Sandborn WJ, Reinisch W, et al., SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. SONIC Study Group. N Engl J Med 2010;15;362:1383-95
30. Peyrin-Biroulet L, Ferrante M, et al., Scientific Committee of the European Crohn's and Colitis Organization. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477-83
31. Danese S, Fiorino G, Fernandes C, Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn's disease. Curr Drug Targets 2014;15;1056-1063
32. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003;18:425-31
33. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94
34. Lee JS, Lee JH, Lee JH, et al. Efficacy of early treatment with infliximab in pediatric Crohn's disease. World J Gastroenterol 2010;16:1776-81